JP2023549017A - 多価担体および関連するワクチン組成物 - Google Patents

多価担体および関連するワクチン組成物 Download PDF

Info

Publication number
JP2023549017A
JP2023549017A JP2023518836A JP2023518836A JP2023549017A JP 2023549017 A JP2023549017 A JP 2023549017A JP 2023518836 A JP2023518836 A JP 2023518836A JP 2023518836 A JP2023518836 A JP 2023518836A JP 2023549017 A JP2023549017 A JP 2023549017A
Authority
JP
Japan
Prior art keywords
coronavirus
protein
vaccine composition
antigens
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518836A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549017A5 (enExample
Inventor
エイ コーエン アレクザンダー
ジェイ ビョークマン パメラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology
Original Assignee
California Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology filed Critical California Institute of Technology
Publication of JP2023549017A publication Critical patent/JP2023549017A/ja
Publication of JP2023549017A5 publication Critical patent/JP2023549017A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2023518836A 2020-11-11 2021-11-10 多価担体および関連するワクチン組成物 Pending JP2023549017A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112495P 2020-11-11 2020-11-11
US63/112,495 2020-11-11
PCT/US2021/058856 WO2022103891A1 (en) 2020-11-11 2021-11-10 Multivalent carriers and related vaccine compositions

Publications (2)

Publication Number Publication Date
JP2023549017A true JP2023549017A (ja) 2023-11-22
JP2023549017A5 JP2023549017A5 (enExample) 2024-11-14

Family

ID=81602587

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518836A Pending JP2023549017A (ja) 2020-11-11 2021-11-10 多価担体および関連するワクチン組成物

Country Status (9)

Country Link
US (2) US12440553B2 (enExample)
EP (1) EP4243867A4 (enExample)
JP (1) JP2023549017A (enExample)
KR (1) KR20230107304A (enExample)
CN (1) CN117098553A (enExample)
AU (1) AU2021378792A1 (enExample)
CA (1) CA3193843A1 (enExample)
IL (1) IL302176A (enExample)
WO (1) WO2022103891A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11740240B2 (en) * 2020-07-20 2023-08-29 Bio-Rad Laboratories, Inc. Immunoassay for SARS-CoV-2 neutralizing antibodies and materials therefor
WO2024006532A2 (en) * 2022-06-30 2024-01-04 La Jolla Institute For Immunology Kari nanoparticle
CN117582492A (zh) * 2022-08-12 2024-02-23 上海市公共卫生临床中心 重组多价疫苗
JP2025529906A (ja) * 2022-08-22 2025-09-09 ザ ヘンリー エム ジャクソン ファンデイション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド コロナウイルスに対するワクチン
CN115894716B (zh) * 2022-11-23 2024-02-09 华中农业大学 一种重组融合蛋白纳米颗粒及其制备方法
CN117362447B (zh) * 2023-08-25 2024-04-09 广东省农业科学院农业生物基因研究中心 一种基于蛋白质偶联聚合体的生物发光酶联免疫分析方法
WO2025255622A1 (en) * 2024-06-13 2025-12-18 University Of Technology Sydney Method of vaccine prototyping

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285289B2 (en) * 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
EP1778283A2 (en) * 2004-06-30 2007-05-02 ID Biomedical Corporation of Quebec Vaccine compositions for treating coronavirus infection
BRPI0611336A2 (pt) 2005-06-01 2010-08-31 Dow Global Technologies Inc método para produzir uma partìcula multivalente semelhante a vìrus, partìcula multivalente semelhante a vìrus, método de aumentar a solubilidade de uma partìcula multivalente semelhante a vìrus e vacina
RU2628690C2 (ru) * 2015-11-06 2017-08-21 Общество С Ограниченной Ответственностью 'Фарминтерпрайсез' Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NATURE IMMUNOLOGY, vol. 20, JPN7025004964, March 2019 (2019-03-01), pages 362 - 372, ISSN: 0005733013 *
SEYHAN BOYOGLU-BARNUM ET AL: "Elicitation of broadly protective immunity to influenza by multivalent hemagglutinin nanoparticle va", BIORXIV, vol. version1, JPN7025004965, 31 May 2020 (2020-05-31), ISSN: 0005733012 *
TIONG KIT TAN ET AL: "A COVID-19 vaccine candidate using SpyCatcher multimeruzation of the SARS-CoV-2 spike protein recept", BIORXIV, vol. version1, JPN7025004967, 31 August 2020 (2020-08-31), ISSN: 0005733010 *
YIN-FENG KANG ET AL: "Rapid development of SARS-CoV-2 receptor binding domain-conjugated nanoparticle vaccine candidate", BIORXIV, vol. version1, JPN7025004966, 3 November 2020 (2020-11-03), ISSN: 0005733011 *

Also Published As

Publication number Publication date
CN117098553A (zh) 2023-11-21
US12440553B2 (en) 2025-10-14
US20260077034A1 (en) 2026-03-19
EP4243867A1 (en) 2023-09-20
EP4243867A4 (en) 2024-09-25
AU2021378792A1 (en) 2023-05-04
IL302176A (en) 2023-06-01
CA3193843A1 (en) 2022-05-19
AU2021378792A9 (en) 2023-07-13
WO2022103891A1 (en) 2022-05-19
US20220168414A1 (en) 2022-06-02
KR20230107304A (ko) 2023-07-14

Similar Documents

Publication Publication Date Title
US12440553B2 (en) Multivalent carriers and related vaccine compositions
Guo et al. Targetable elements in SARS-CoV-2 S2 subunit for the design of pan-coronavirus fusion inhibitors and vaccines
CN111991556B (zh) SARS-CoV-2 RBD共轭纳米颗粒疫苗
US10117924B2 (en) Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions
CN113801207B (zh) 新型冠状病毒的串联表位多肽疫苗及其应用
JP5894528B2 (ja) 抗原−ノロウイルスｐドメインモノマーおよびダイマー、抗原−ノロウイルスｐ粒子分子、ならびにそれらの製造および使用法
JP2021519596A (ja) フェリチンタンパク質
JP2022549791A (ja) ジフテリア毒素交差反応物質（ｃｒｍ）アミノ酸配列を含むタンパク質粒子及びその使用
EP4653453A1 (en) Recombinant chimeric antigen for poxvirus, subunit vaccine comprising same and use thereof
CN114835819A (zh) SARS-CoV-2 S1偶联纳米颗粒及其应用
ES2854726T3 (es) Partícula similar a virus con presentación eficiente de epítopos
KR102765237B1 (ko) Rsv의 f 단백질-항체 복합체 및 이를 포함하는 조성물
EP4347622A1 (en) Reconstitution and uses of flavivirus epitopes
US20250011396A1 (en) Multivalent carriers and related vaccine compositions
KR102873285B1 (ko) 스캐폴드 기반의 다중항원을 포함하는 코로나바이러스 감염병 예방 또는 치료용 항원 조성물
CN108430502A (zh) 诺瓦克病毒疫苗
US20240424087A1 (en) Multiepitope self-assembled nanoparticle vaccine platform (msn-vaccine platform) and uses there of
JP2018531256A6 (ja) デングウイルスワクチンおよび診断のための方法および組成物
JP2018531256A (ja) デングウイルスワクチンおよび診断のための方法および組成物
CN107557347A (zh) 肠道病毒71型的新型病毒样颗粒、其制备方法及应用
Geng Receptor recognition of SARS-CoV-2 and vaccine design
Cohen et al. Neutralization of SARS-CoV-2 and zoonotic coronavirus threats by mosaic nanoparticle vaccination
WO2022253193A1 (zh) 一种新型冠状病毒疫苗多肽及其纳米乳制剂在预防新冠野毒株和突变株感染中的应用
WO2025081050A1 (en) Coronavirus stem helix and fusion peptide nanoparticle vaccines
Frey Engineering Viral Protein Antigens that Direct the Humoral Immune Response to Conserved Epitopes

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260428